Yes, tPA is acceptable for subsequent cerebral infarctions when administered within appropriate time windows and eligibility criteria are met.
IV tPA should be offered to patients with subsequent acute ischemic strokes who meet NINDS inclusion/exclusion criteria and can be treated within 3 hours of symptom onset, and should be considered for those meeting ECASS III criteria within 3 to 4.5 hours 1, 2. The evidence does not distinguish between first-time and recurrent strokes in terms of tPA eligibility—the critical factors are timing, imaging findings, and meeting standard inclusion/exclusion criteria.
Key Decision Points for Subsequent Strokes
Time-Based Treatment Algorithm
Within 3 hours of symptom onset:
- Level A recommendation: Offer IV tPA (0.9 mg/kg, maximum 90 mg) to improve functional outcomes 1, 3
- NNT = 8 for better long-term functional outcome
- NNH = 17 for symptomatic intracranial hemorrhage (sICH) 2
- This applies regardless of whether it's a first or subsequent stroke
Between 3 to 4.5 hours:
- Level B recommendation: Consider IV tPA using ECASS III criteria 1, 2
- NNT = 14 for improved functional outcomes
- NNH = 23 for sICH 2
- Note: This extended window is not FDA-approved but is guideline-supported 1
Beyond 4.5 hours:
- Level 1B recommendation: Do NOT administer IV tPA 3
- Exception: Selected patients with advanced neuroimaging may qualify for extended windows 4
Critical Eligibility Assessment
The standard NINDS and ECASS III inclusion/exclusion criteria apply equally to subsequent strokes. There is no automatic exclusion for patients who have had prior strokes. Key considerations:
- Exclude intracranial hemorrhage via noncontrast CT or MRI 5
- Assess extent of ischemic changes on imaging
- Verify no contraindications (recent surgery within 48 hours, active bleeding, severe hepatic/renal disease) 6
- Evaluate mechanical causes of symptoms before assuming thrombus 6
Important Caveats for Subsequent Strokes
Prior stroke is NOT a contraindication unless:
- The patient has residual deficits that would confound outcome assessment
- There is evidence of old hemorrhagic transformation
- The cumulative stroke burden creates unacceptable bleeding risk
Institutional readiness matters: The effectiveness of tPA is less well established in institutions without proper systems to safely administer the medication 1. This applies even more critically to patients with complex histories like recurrent strokes.
Shared Decision-Making
When feasible, discuss with the patient/surrogate 2:
- Potential benefit: 30-50% increased probability of favorable functional outcome depending on time window
- Hemorrhage risk: 4-6% risk of symptomatic ICH (approximately 4-6 times higher than placebo)
- Mortality: No significant difference in 90-day mortality 2
Patients tend to overestimate benefits and underestimate harms—provide specific numbers 2.
Practical Implementation
- Imaging first: Obtain noncontrast CT or MRI immediately to exclude hemorrhage 5
- Don't delay for additional imaging: If patient meets criteria and vascular imaging isn't immediately available, start tPA before transferring for advanced imaging 7
- Treat as rapidly as possible: Earlier treatment = better outcomes within any time window 1
- Consider endovascular therapy: If large vessel occlusion is suspected, vascular imaging (CTA/MRA) should be performed during initial evaluation 5, 7
The evidence base for tPA in acute ischemic stroke does not differentiate between index and recurrent events—eligibility is determined by current presentation characteristics, not stroke history.